Advertisement
Advertise on MSK
Musculoskeletal Report
January 04, 2011
MSK Report Video Podcasts

Meeting Highlights

ISEMIR 2009: Video coverage of the Meeting
Miami, March 27, 2009
RWCS 2009: Video coverage of the Symposium
Maui, January 14-17, 2009
ACR 2008: News from the Annual Scientific Meeting
San Francisco, October 24-29, 2008
EULAR 2008: Coverage of the Congress
Paris, June 11-14, 2008
ISEMIR 2008: Video coverage of the Meeting
Chicago, April 10, 2008
AAOS 2008: News from the Annual Meeting
San Francisco, March 5-9, 2008

Affiliations

Arthritis Research
Lupus Research Institute - Letting Science Lead the Way to a Cure
RSS Feeds
advertisement
Alvin F. Wells, MD: DVD Series

MSK MeetingRheum

MSK Report News

Click here to register for ISEMIR 2010

BioPharm Business News

Thursday, March 12, 2009
Judge Puts Generic Evista on Hold
A US District Court has put a 10-day hold on Teva Pharmaceuticals' plan to launch a generic version of Eli Lilly's Evista (raloxifene) osteoporosis drug...

Thursday, March 05, 2009
First Nonsurgical Dupuytren's Rx Likely to Be Auxilium's Xiaflex
Auxilium Pharmaceuticals is requesting expedited approval for Xiaflex™ (clostridial collagenase for injection), a nonsurgical treatment for Dupuytren's contracture...

Thursday, February 26, 2009
Pfizer Stops Work on Esreboxetine for FM
Pfizer has stopped development of esreboxetine, which was in phase II trials for fibromyalgia...

Thursday, February 19, 2009
Raptiva® Pulled in EU After 3rd PML Case; FDA Warns US Docs
European regulators suspended sales of the psoriasis drug Raptiva® after a 3rd PML death, and the FDA warned US doctors of a 4th suspected case...

Monday, February 16, 2009
FDA Gives Nod to Uloric® (febuxostat), First New Gout Treatment in 40 Years
The US FDA approved 40 mg and 80 mg doses of Takeda Pharmaceutical's febuxostat (Uloric) for the chronic management of hyperuricemia in patients with gout...

Friday, February 13, 2009
La Jolla and Biomarin Dump Riquent, Cite “Futile” Phase 3 Lupus Data
La Jolla Pharmaceutical has ended work on Riquent® (abetimus sodium)after the first interim efficacy analysis for the ASPEN Phase 3 lupus nephritis trial...